AstraZeneca’s Puja Sapra says AI is shortening biologics cycle times with fewer dead ends
The build-measure-learn loop, proprietary multimodal data, and a Kendall Square “lab of the future” are reshaping drug R&D.
By Omar Al-Balawi·· 4 min
Loading the Newsroom
Curating from trusted global sources…